

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Sunday, March 27, 2005

| Hide? | <u>Set Name</u> | <u>Query</u> | <u>Hit Count</u> |
|--------------------------|--|--|------------------|
| | <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i> | | |
| <input type="checkbox"/> | L7 | wnt same (affinity chromatography) same detergent | 2 |
| <input type="checkbox"/> | L6 | wnt same (protein\$ or peptide\$) | 959 |
| <input type="checkbox"/> | L5 | L4 and wnt | 4 |
| <input type="checkbox"/> | L4 | L3 and detergent | 327 |
| <input type="checkbox"/> | L3 | L2 and (non adj2 ionic or zwitterionic) | 570 |
| <input type="checkbox"/> | L2 | (affinity chromatography) same (dye ligand) same (gel exclusion) | 5809 |
| <input type="checkbox"/> | L1 | (affinity chromatography) same (dye ligand) and (gel exclusion) | 28844 |

END OF SEARCH HISTORY

10/816,720

(FILE 'HOME' ENTERED AT 21:50:14 ON 27 MAR 2005)

FILE 'STNGUIDE' ENTERED AT 21:52:06 ON 27 MAR 2005

FILE 'HOME' ENTERED AT 21:52:11 ON 27 MAR 2005

FILE 'REGISTRY' ENTERED AT 21:53:57 ON 27 MAR 2005

L1 0 S KAGIQECQHQFRGRRWNCTTVS/SQEP
L2 0 S KAGIQECQHQFRGRRWNCTTVS/SQEP
L3 7 S KAGIQECQHQFRGRRWNCTTVS/SQSP
L4 0 S KQALDSCQQSFQWQRWNCPSQD/SQEP
L5 3 S KQALDSCQQSFQWQRWNCPSQD/SQSP
L6 0 S NLAISECQHQFRNRRWNCSTRN/SQEP
L7 13 S NLAISECQHQFRNRRWNCSTRN/SQSP
L8 0 S REAIRECENKFKFERWNCSSRD/SQEP
L9 2 S REAIRECENKFKFERWNCSSRD/SQSP
L10 0 S L3 AND SQL<=30
L11 7 S L3 AND SQL<=500
L12 0 S L3 AND SQL<=100

FILE 'CAPLUS' ENTERED AT 22:15:00 ON 27 MAR 2005

L13 0 S L7 AND WNT
L14 0 S L5 AND WNT
L15 5 S L3
L16 3 S L5
L17 7 S L7
L18 1 S L9
L19 5 S L15 AND WNT
L20 0 S L16 AND WNT
L21 0 S L17 AND WNT
L22 1 S L18 AND WNT

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,

BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,

CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 22:19:37 ON 27 MAR 2005

SEA WNT AND (PURIF? OR ISOLAT?)(P) AFFINITY CHROMATOGRAPHY

L23 QUE WNT AND (PURIF? OR ISOLAT?)(P) AFFINITY CHROMATOGRAPHY

SEA L23 AND DETERGENT

L24 QUE L23 AND DETERGENT

SEA L24 AND GEL EXCLUSION

L25 QUE L24 AND GEL EXCLUSION

SEA L4 AND (PEPTIDE OR PROTEIN) AND DYE LIGAND

SEA L24 AND (PEPTIDE OR PROTEIN) AND DYE LIGAND

L26 QUE L24 AND (PEPTIDE OR PROTEIN) AND DYE LIGAND

FILE 'DGENE, IFIPAT, USPATFULL, WPINDEX' ENTERED AT 22:34:38 ON 27
MAR

2005

L27 510 S L24

L28 12 S L26

L29 11 DUP REMO L28 (1 DUPLICATE REMOVED)

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:94745 CAPLUS

DN 130:249737

TI A **Wnt** signaling pathway controls hox gene expression and neuroblast migration in *C. elegans*

AU Maloof, Julin N.; Whangbo, Jennifer; Harris, Jeanne M.; Jongeward, Gregg D.; Kenyon, Cynthia

CS Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, 94143-0448, USA

SO Development (Cambridge, United Kingdom) (1999), 126(1), 37-49
CODEN: DEVPED; ISSN: 0950-1991

PB Company of Biologists Ltd.

DT Journal

LA English

AB The specification of body pattern along the anteroposterior (A/P) body axis is achieved largely by the actions of conserved clusters of Hox genes. Limiting expression of these genes to localized regional domains and controlling the precise patterns of expression within those domains is critically important for normal patterning. Here we report that *egl-20*, a *Caenorhabditis elegans* gene required to activate expression of the Hox gene *mab-5* in the migratory neuroblast QL, encodes a member of the **Wnt** family of secreted glycoproteins. We have found that a second **Wnt** pathway gene, *bar-1*, which encodes a β -catenin/Armadillo-like protein, is also required for activation of *mab-5* expression in QL. In addition, we describe the gene *pry-1*, which is required to limit expression of the Hox genes *lin-39*, *mab-5*, and *egl-5* to their correct local domains. We find that *egl-20*, *pry-1*, and *bar-1* all function in a linear genetic pathway with conserved **Wnt** signaling components, suggesting that a conserved **Wnt** pathway activates expression of *mab-5* in the migratory neuroblast QL. Moreover, we find that members of this **Wnt** signaling system play a major role in both the general and fine-scale control of Hox gene expression in other cell types along the A/P axis.

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

SEO #4
from C22

AN 1991:507474 CAPLUS

DN 115:107474

TI Expression of two members of the **Wnt** family during mouse development - restricted temporal and spatial patterns in the developing neural tube

AU Roelink, Henk; Nusse, Roel

CS Howard Hughes Med. Inst., Stanford, CA, 94305, USA

SO Genes & Development (1991), 5(3), 381-8

CODEN: GEDEEP; ISSN: 0890-9369

DT Journal

LA English

AB The **Wnt** gene family encodes a group of cysteine-rich proteins implicated in intercellular signaling during several stages of vertebrate development. This family includes **Wnt-1** and **Wnt-3**, both discovered as activated oncogenes in mouse mammary tumors. Here the authors describe the mol. cloning of an addnl. member of the **Wnt** family, called **Wnt-3A**, and the spatial and temporal expression pattern of this gene as well as that of its close relative **Wnt-3**. The putative amino acid sequences of both proteins are almost 90% identical, but in situ hybridization to mouse embryo sections showed highly restricted patterns of expression of **Wnt-3** and **Wnt-3A**, largely in sep. areas in the developing nervous system. In the spinal cord **Wnt-3** was expressed at low levels in the alar laminae and in the ventral horns, whereas **Wnt-3A** expression was confined to the roof plate. In the developing brain **Wnt-3** was expressed broadly across the dorsal portion of the neural tube with a rostral boundary of expression at the diencephalon. In contrast, **Wnt-3A** was expressed in a narrow region very close to the midline; expression extended into the bifurcating telencephalon, in a highly localized fashion. Both **Wnt-3A** were expressed in the ectoderm, and **Wnt-3A** was also expressed in the periumbilical mesenchyme. Characteristic expression patterns of these two closely related genes suggest that **Wnt-3** and **Wnt-3A** play distinct roles in cell-cell signaling during morphogenesis of the developing neural tube.

ALL
L19 SEQ ID #1

AN 1999:723151 CAPLUS
 DN 131:335410
 TI Induction of neuronal regeneration
 IN McMahon, Andrew P.; Lee, Scott K.; Takada, Shinji
 PA President and Fellows of Harvard College, USA
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 9957248 | A1 | 19991111 | WO 1998-US8716 | 19980430 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |

PRAI WO 1998-US8716 19980430

AB An enriched population of mammalian dorsal neural progenitor cells, e.g., dopaminergic neural precursor cells, are described that are useful to induce neuronal regeneration in mammals suffering from a neurodegenerative disease.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2002:240809 CAPLUS

DN 136:274307

TI Protein and cDNA sequences of novel human protein NOV and use in diagnosis and disease treatment

IN Mishra, Vishnu S.; Syptek, Kimberly Ann; Taupier, Raymond J., Jr.; Vernet, Corine A. M.; Colman, Steven D.; Gorman, Linda; Tchernev, Velizar T.; Malyankar, Uriel M.; Shenoy, Suresh; Tchernev, Velizar T.; Padigaru, Muralidhara; Patturajan, Meera; Burgess, Catherine E.; Smithson, Glennda; Millet, Isabelle; Peyman, John A.; Stone, David; Gunther, Erik; Ellerman, Karen

PA Curagen Corporation, USA

SO PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 155

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002024733 | A2 | 20020328 | WO 2001-US29115 | 20010917 |
| | WO 2002024733 | A3 | 20030703 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2421576 | AA | 20020328 | CA 2001-2421576 | 20010917 |
| | AU 2001092734 | A5 | 20020402 | AU 2001-92734 | 20010917 |
| | EP 1360291 | A2 | 20031112 | EP 2001-973124 | 20010917 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2004529607 | T2 | 20040930 | JP 2002-529141 | 20010917 |
| PRAI | US 2000-232675P | P | 20000915 | | |
| | US 2000-232676P | P | 20000915 | | |
| | US 2000-232679P | P | 20000915 | | |
| | US 2000-233382P | P | 20000918 | | |
| | US 2000-233402P | P | 20000918 | | |
| | US 2000-233521P | P | 20000919 | | |
| | US 2000-233522P | P | 20000919 | | |
| | US 2000-233801P | P | 20000919 | | |
| | US 2000-233960P | P | 20000920 | | |
| | US 2000-238398P | P | 20001006 | | |
| | US 2000-240498P | P | 20001013 | | |
| | US 2001-260284P | P | 20010108 | | |
| | US 2001-260973P | P | 20010111 | | |
| | US 2001-264794P | P | 20010129 | | |
| | US 2001-274862P | P | 20010309 | | |
| | WO 2001-US29115 | W | 20010917 | | |

AB The invention relates to 16 human protein NOV. Disclosed herein are proteins which are homologous to *Wnt*, zinc transporter, Mitsugumin29, slit-3, LRR/GPCR, major histocompatibility complex enhancer protein MAD3, interleukin 9, 5-hydroxytryptamine receptor, and thioredoxin related polypeptides. The invention also relates to single nucleotide polymorphism found in gene NOV1a, NOV1b, NOV3a, NOV4a, NOV4b and NOV6. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.